GlassScriptPhysician profile
Marina B Molitor
NPI 1174886063
$13,344.23
in general payments reported to CMS, 2019-2025
56 companies · $2,565 in 2025
The $2,565 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,770 · 2022: $2,695 · 2023: $2,030 · 2024: $3,285 · 2025: $2,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,879.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,628.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,585.70 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,367.70 | 2021-2025 | |
| Lilly USA, LLC | $1,171.93 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $775.35 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.81 | 2021-2025 | Jardiance, Tradjenta, Trijardy Xr |
| Novartis Pharmaceuticals Corporation | $411.56 | 2021-2025 | |
| Gilead Sciences, INC. | $401.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.09 | 2021-2025 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $368.64 | 2021-2023 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $342.29 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $289.32 | 2024-2025 | Rexulti |
| Antares Pharma, INC. | $278.54 | 2021-2025 | Xyosted |
| Almatica Pharma LLC | $277.79 | 2021-2025 | Loreev Xr, Sertraline Hcl, Gralise |
| Exact Sciences Corporation | $273.81 | 2023-2025 | Cologuard Collection Kit |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Molitor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.